Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Recruiting

Phase 1

Phase 2

Luveltamab TazevibulinLuveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Sponsor:

Sutro Biopharma, Inc.

Code:

NCT06679582

Conditions

Acute Myeloid Leukemia (AML)

Eligibility Criteria

Sex: All

Age: 1 - 12

Healthy Volunteers: Not accepted

Interventions

Luveltamab tazevibulin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-23. This information was provided to ClinicalTrials.gov by Sutro Biopharma, Inc. on 2024-12-17.